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Simple Summary: This manuscript revises the harmonised management of side effects related
to the use of certain drugs to treat cancer called checkpoint inhibitors. These drugs activate
immune responses against tumour cells and by doing so they may also induce immune responses
against self-tissues leading to clinical manifestations that affect several organs and systems.
The complexity of this scenario requires a multidisciplinary care, integrating several health
professionals (specialized nurses, prescribers, and non-prescriber specialists) that consider all
treatment options and develop an individual treatment plan for each patient aiming to guarantee
the best patient care. The recommendations presented here are based on current guidelines for the
management of organ-specific immune-related adverse events.
Abstract: Immune-oncology is a major breakthrough in cancer treatment and has become the
standard of care for a wide variety of solid organ malignancies. Unfortunately, manipulation of
the immune system with checkpoint inhibitors may result in an immune-based attack of normal
tissues which can lead to treatment discontinuation. These immune-related adverse events (irAEs) are
diverse and affect several organs, constituting a new clinical challenge in the management of cancer
patients. The complexity of this scenario requires a multidisciplinary approach that allows the early
identification, diagnosis and treatment of specific irAE, ruling out other non-related adverse events.
Hospital Clinic has a multidisciplinary team seeking to develop a coordinated strategy to facilitate
the access of patients with suspected irAEs to specialised care resulting in harmonised management
that guarantees the best patient care. The aim of the manuscript was to describe the current evidence
on the management of irAEs reflecting a coordinated multidisciplinary approach to face this clinical
challenge regardless of the immunotherapy indication.
Keywords: immune checkpoint inhibitors; immune-oncology; immune-related adverse events;
protocols; multidisciplinary approach
1. Introduction
Cancer immunotherapy has become the standard of care for a wide variety of solid organ
malignancies. It provides the unprecedented opportunity to treat, and in some cases, achieve long-term
complete remissions of several previously untreatable cancers [1]. This occurs in the era of the “silver
oncologic tsunami” and growing numbers of long-term cancer survivors with frequent comorbidities.
Currently, the most commonly used approach is the administration of immune checkpoint inhibitors
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(ICPI). These drugs block proteins with critical function as negative regulators of T cell activation [2–4].
CTLA-4 suppresses the activation of T cells by out-competing with CD28 for the ligation with CD86
and CD80 of antigen presenting cells (APC). In addition, CTLA-4 expression in regulatory T cells
(Tregs) can directly remove CD86 and CD80 from the surface of activated APC by trans-endocytosis [5].
Monoclonal antibodies against CTLA-4 (ipilimumab, tremelimumab) induce T cell activation and lead
to a depletion of Tregs within the tumour. When PD-1 binds its receptor (PD-L1, expressed in tumour
cells, epithelial cells, dendritic cells, macrophages and fibroblasts; or PD-L2, only expressed in APC),
T cell activation is inhibited [6]. PD-1 (nivolumab, pembrolizumab, cemiplimab)/PDL-1 (atezolizumab,
durvalumab, avelumab) axis blockade reverts these changes, and therefore, constitutes the pillar of
current anti-cancer immunotherapy [7].
Different drugs are now approved for the treatment of multiple cancer types either in monotherapy
or in combination with other agents as first-line treatment or when standard treatment has failed
(Table S1). Nowadays, immunotherapy has demonstrated to achieve response in a subset of cancers,
although it is still difficult to precisely determine which patients will benefit [8]. New strategies based on
pharmacokinetic and pharmacodynamic monitoring, as a means of improving exposure and predicting
individual response to ICPI, have not yet been fully evaluated to guide dose individualization [9].
Unfortunately, the manipulation of the immune system with these drugs can result in an
immune-based attack on healthy tissues. Its consequences are diverse and can potentially affect every
organ [7] constituting a new clinical challenge in the management of cancer patients. Anti-PD-1 and
anti-CTLA-4 blockers present different mechanisms of action, acting on different sites and affecting
distinct lymphocyte subtypes. Their concomitant use results in a higher incidence and broader
spectrum of adverse events (AEs), also known as immune-related adverse events (irAEs). Some studies
suggest that the development of irAE may be associated with better anti-tumour responses. However,
this finding may differ between cancer types and specific drugs and there is still poor knowledge
regarding that issue. The complexity of this scenario requires multidisciplinary care, which can be
defined as an integrated team approach in which health professionals consider all treatment options
and develop an individual treatment plan for each patient [10]. A multidisciplinary approach for
cancer care has been recommended by cancer organizations, governments and societies since 1995 [11].
Traditionally, these groups are composed by expert clinicians from the different specialties involved in
the care pathway of each tumour according to its primary location (medical and radiation oncologists,
dermatologists, urologists, gynaecologists, haematologists, neurologists, hepatologists, pneumologists,
gastroenterologists, endocrinologists, internists, rheumatologists, surgeons, radiologists, pathologists,
intensive care specialists, specialised nurses, psychologists, etc.).
In 2018, our hospital created a multidisciplinary team seeking to develop a coordinated
strategy to facilitate the access of patients with suspected irAEs to specialised care. As a result,
harmonised protocols were designed to assure the best irAE management and provide state of the
art medical care for both conventional practice and research (Figure 1). Here, we summarise the
current evidence and propose a coordinated strategy to face the current clinical challenge posed by
cancer immunotherapy-irAEs.
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Figure 1. Workflow of the multidisciplinary approach to the management of immune-related adverse
events (irAEs).
2. Coordinated Management of irAEs
2.1. Skin
Dermatological toxicity is considered the most frequent ICPI-induced AE, which is usually the first
to appear (even within the first weeks of treatment) and is rarely severe. As a result, these AEs usually
do not lead to ICPI treatment modification [12,13]. However, dermatological complications can develop
at any time during treatment, even after discontinuation. On rare occasions, serious immune-mediated
dermatosis may appear—the so called severe dermatological adverse event (SDAE) [14,15]. Therefore,
early dermatological evaluation is crucial to ensure accurate recognition and management in early
stages of the toxicity. That is the case of potential life-threating syndromes such as toxic epidermolytic
necrolysis (TEN), the Stevens–Johnsons syndrome (SJS), drug rash with eosinophilia and systemic
symptoms (DRESS) or acute generalised exanthematous pustulosis (AGEP). The most important
criteria to suspect a potential severe dermatological AE are summarised in Figure S1.
Approximately 1 out of 3 patients treated with ICPI develop a dermatological irAE; 45% with
anti-CTLA4, 35% with anti-PD1 and rising two-fold when used in combination (anti-CTLA4 + anti-PD1).
Less than 5–8% of patients develop grade 3 to 4 dermatological toxicity (around 2–3% with monotherapy
and 5% with combined therapy).
Skin rash is the most frequent irAE (15% in anti-PD1, 25% in anti-CTLA4 and 40% in combination);
erythematous unspecific self-limited exanthema can appear very early, but the most specific irAE
consists of a lichenoid exanthema. It can present the same features as an idiopathic lichen planus
rash (Figure 2A,B) on the skin and/or mucosae or may show more diffuse involvement such as that
of drug-induced lichenoid. Vitiligo-like depigmentation, which presents with hypo-pigmented or
white macules usually on the trunk and sun-exposed areas, can be observed especially in melanoma
patients treated with ICPI (less than 10%). This side effect has been most strongly associated with better
response to therapy and improved outcomes in melanoma patients; however, prospective, long-term
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follow-up studies are necessary to confirm this association [16,17]. Vitiligo-like macules do not need
specific treatment. Pruritus was initially reported in about 25–35% of cases, although it is probably less
frequent, at least at a high enough grade to require specific management which is estimated to occur
in about 15% of cases. However, up to 2% of cases can reach grade 3–4 pruritus in which the patient
cannot tolerate ICPI therapy.
Figure 2. (A) Severe and erosive lichen planus-like lesions with involvement of skin and nails and (B) of
mucosa, after 3 cycles of nivolumab. (C) Cutaneous involvement of sarcoid-like granulomatous lesions
developed after cessation of pembrolizumab. (D) Granulomatous lesion in skin biopsy, magnified
40 times.
Several types of dermatosis can be induced or exacerbated during or after ICPI therapy.
Most involve immune-mediated disorders probably in predisposed individuals. Some of these
diseases include psoriasis, autoimmune blistering diseases and connective tissue disorders, Grover’s
disease, alopecia areata, xerosis, urticaria, among others. In view of this wide differential diagnosis,
dermatological consultation is strongly recommended. Granulomatous disorders can also be early
detected on the skin, and the most frequent organ involved is the lung and hiliar lymph nodes.
Sarcoid-like granulomas can pose a diagnostic challenge to be differentiated from metastatic disease
(Figure 2C,D).
Management of these skin diseases depends on the definite dermatological diagnosis, but the
treatment of most dermatological irAEs is usually based on symptomatic oral therapy for pruritus
with antihistamine drugs, and topical and/or oral corticosteroids, not requiring ICPI modifications.
Treatment recommendations are based on the Common Terminology Criteria for Adverse Events
(CTCAE) classification, generally based on the extension of the rash on the body surface as well as
patient tolerability. Table 1 shows the protocol for skin rash [18].
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Table 1. Multidisciplinary approach to monitoring and treatment of immune-related adverse events.
Organ Grade 1 Grade 2 Grade 3 Grade 4
Skin rash
-Physical examination





















-Management as grade 2 +
oral prednisone
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-For severe rash IV
methylprednisolone
(0.5–1 mg/kg) and convert
to oral prednisone
depending on response,
wean over 2–4 weeks;
-Resume ICPI at
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methylprednisolone
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biopsy or worsening (72 h);













-AZA, MMF, or Tac if
no response;
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Table 1. Cont.
Organ Grade 1 Grade 2 Grade 3 Grade 4


















-Central involvement: EEG, brain/ spine MRI, CSF
and antibody studies. Empiric antibacterial and
antivirals;-Peripheral involvement: EMG, CK and
antibody study, vital capacity, cardiac monitoring
to detect overlap syndromes;
-Hospital admission, ICU monitoring or support;
-Discontinue ICPI treatment;
-Avoid medications that may worsen myasthenia;
-IV methylprednisolone (1 gr × 3–5 days);
-If partial or no improvement within one week IVIG
(2 g/kg over 5 days) or plasma exchange;
-Consider rituximab/ cyclophosphamide in
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(250 mg/day for 3 days)









































BSA: body surface area, DAE: dermatologic adverse event, AGPP: acute generalised pustular psoriasis, TEN: toxic
epidermal necrolysis, DRESS: drug rash with eosinophilia and systemic symptoms, IV: intravenous, ICPI: immune
checkpoint inhibitors, IFX: infliximab, VDZ: vedolizumab, GI: gastrointestinal; CT: computed tomography, NSAID:
non-steroidalanti-inflammatory drugs, EEG: electroencephalogram; MTX: methotrexate, LEF: leflunomide, INR:
International normalised ration, AZA: azathioprine, MMF: mofetil mycophenolate, Tac: tacrolimus, MRI: magnetic
resonance imaging, CSF: cerebrospinal fluid, EMG: electromyography, CK: creatine kinase, ICU: intensive care
unit, IVIG: intravenous immunoglobulin, WBC: white blood cells, ATIN: acute tubolintersticial nephritis. * Liver
dysfunction is defined as bilirubin >2.5 mg/dL, coagulopathy (INR >1.5) and/or hepatic encephalopathy.
Other immune-modulator drugs, such as azathioprine, cyclosporine or mofetil mychophenolate,
may be of benefit in cases presenting irAEs, and individual management must be discussed. In the case
of the development of SDAE, early vital and general support by a referral centre is essential, and the
ICPI usually has to be definitely discontinued.
2.2. Gastrointestinal Tract
Among all the irAEs associated with ICPI, gastrointestinal (GI) toxicity is one of the most frequent
and severe, being diarrhoea and colitis the most prevalent [19]. Colitis must be suspected when
diarrhoea is accompanied by abdominal pain and/or rectal bleeding. More severe cases may resemble
inflammatory bowel disease (IBD). Enteritis, esophagitis, necrotizing gastritis and pancreatitis are rare
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but have also been reported. Microscopic colitis has also been described, being histological diagnosis
mandatory for the establishment of diagnosis.
The incidence of diarrhoea and colitis related to CTLA-4 inhibitors is higher at 35% and 10%,
respectively and more severe compared to that induced by PD-1 blockade with 20% and 1.6%,
respectively [20,21]. The frequency and severity of GI toxicity is dose-dependent and increases when
the two drugs are given in combination. The median time to symptom onset is 8 weeks for ipilimumab
compared to 3–6 months for nivolumab [22]. The severity of GI toxicity is established in four categories
according to the CTCAE (Common Terminology Criteria for Adverse Events) classification. This scale
considers symptoms including diarrhoea, abdominal pain, blood or mucus in the stools, incontinence
and fever. In the most serious cases life-threatening conditions such as haemorrhage, perforation and
toxic megacolon may appear. Colonic perforation has been described in up to 6% of patients treated
with ipilimumab.
The diagnostic algorithm depends on the severity of the symptoms. In all cases, the initial workup
should include a complete blood count, serum electrolyte profile, C reactive protein (CRP), renal and
thyroid function, and stool cultures to rule out infections (bacteria and Clostridium difficile). In moderate
to severe cases, an abdominal CT and colonoscopy are recommended. Two distinct patterns of clinical
and radiographic manifestations of ICPI-related colitis have been reported. The most common is
a diffuse unspecific colitis pattern, characterised by mild diffuse bowel wall thickening or colonic
distension with prominent pericolonic vessel engorgement. Another less common pattern is segmental
colitis associated with sigmoid diverticula. In these cases, both colonic wall thickening and perienteric
inflammation are more evident, resembling an infectious diverticulitis, but patients usually have a
paucity of systemic symptoms [23,24]. Full colonoscopy with biopsies is advisable since sigmoidoscopy
may underestimate the extent and severity of the lesions (up to 8% of patients may have lesions limited
to the ascending colon). Around 75% of patients present extensive colitis with a continuous pattern
of inflammation in 45–79% [25]. Endoscopic findings may resemble infectious conditions and IBD
(erythema, loss of vascular pattern, friability, ulcers and mucosal bleeding). Severe endoscopic lesions
and pancolitis correlate with the need for rescue therapy with infliximab [26,27]. Biopsies are mandatory
to establish an adequate diagnosis (rule out the presence of cytomegalovirus). In cases of normal
appearance of the mucosa, biopsies should also be obtained in order to rule out microscopic colitis.
Mild cases of diarrhoea can be managed with symptomatic treatment including a low-fibre diet
or anti-diarrhoeal drugs such as loperamide and oral fluids. Immunotherapy can be continued in
mild cases. In moderate or mild cases not responding to symptomatic treatment, oral corticosteroids
(1 mg/kg) must be started and tapered within 8–12 weeks. All severe cases must receive intravenous
corticosteroids (1–2 mg/kg) together with supportive measures. In moderate and severe cases,
immunotherapy must be discontinued until the condition has resolved. Although the response
rates to corticosteroids are high (80%), a non-negligible proportion of patients (20%) present steroid
refractoriness. Early identification and adequate treatment of this situation (persistent elevated CRP
and/or blood in the stools after 3–5 days of treatment) is crucial to reduce morbidity and mortality.
Patients not responding to intravenous corticosteroids within 3–5 days should be treated with infliximab
(5 mg/kg) [28–30]. A single dose is often enough for improving symptoms, although a second or
even third dose may be needed 2 and 6 weeks later, respectively. Vedolizumab, a monoclonal
antibody blocking α4β7 integrin, has recently shown to be effective in a small series of patients
with steroid-dependent, steroid-refractory and infliximab refractory immune-mediated colitis [31,32].
In extremely severe cases, patients may require emergency subtotal colectomy (megacolon, colonic
perforation) (Table 1).
2.3. Lung
Immune-mediated pulmonary toxicity, known as pneumonitis and defined as local or diffuse
inflammation of the lung parenchyma secondary to treatment [33], is a rare adverse effect (2.7%) and
may be severe in some cases (0.8%) [34]. Pneumonitis (of any degree or severity) is more prevalent
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in patients with non-small cell lung carcinoma as compared to other tumours such as melanoma
(4.1% vs. 1.6% and 1.8% vs. 0.2%, respectively) [35]. Similar to other irAEs, pneumonitis is more
frequent and severe in patients receiving combined treatments (6.6% vs. 1.6% in patients treated
with only one ICPI) [35]. In addition to the typical pulmonary involvement due to pneumonitis,
other immune-mediated pulmonary toxicities such as tracheobronchial involvement, sarcoid reactions
and pleural effusion may be presented, albeit less frequently. The clinical manifestations reported in the
different studies consist of non-specific respiratory symptoms such as dyspnoea (53%) and cough (35%),
although they can also manifest with fever (12%) and chest pain (7%). AEs may be asymptomatic in 33%
of patients [12]. Pneumonitis is classified according to the adaptation of the CTCAE clinical criteria [12]:
grade (G)1 (asymptomatic, only associated radiological changes), G2: (mild or moderate symptoms),
G3 (severe symptoms, need for oxygen therapy) and G4 (respiratory failure, need for intubation or
tracheostomy). The clinical guidelines of the European Oncology Society (ESMO) [36] recommend the
following complementary tests for suspected immune-mediated pneumonitis: (1) Conventional chest
X-ray, as the initial diagnostic test on suspicion of any degree of pneumonitis; (2) thoracic high-resolution
computed tomography, indicated in pneumonitis ≥G2; (3) bronchoscopy and bronchoalveolar lavage
with microbiological and cytological study in ≥G2 pneumonitis in order to rule out other infectious or
concomitant processes of pharmacological toxicity. In G1 pneumonitis, symptomatic treatment and
delay of ICPI treatment and revaluation according to evolution is recommended. In G2 pneumonitis,
it is advisable to suspend ICPI treatment and initiate oral or intravenous corticosteroid treatment at a
dose of 1 mg/kg per day. In G ≥ 3 pneumonitis, immunotherapy treatment should be permanently
discontinued and intravenous corticosteroids should be initiated at a dose of 2–4 mg/kg/day (Table 1).
2.4. Rheumatic and Systemic Autoimmune Syndromes
There is an increase of the number of reports of rheumatic and systemic autoimmune syndromes
induced by ICPI, due to increased usage of ICPI as well as better recognition of these new
associations [37]. Overall, according to some recent reports, these syndromes occur in around 5–10%
of patients receiving ICPI [38–43], although randomised clinical trials may sometimes underreport
and/or misclassify these syndromes as musculoskeletal disorders. These irEAs can be grouped into
four different categories: (1) inflammatory arthritis, (2) non-inflammatory arthralgias, (3) polymyalgia
rheumatic-like (PMR) syndromes and (4) a miscellaneous group of systemic or localised disorders
including vasculitis, sicca symptoms and scleroderma- and sarcoid-like reactions.
The time to onset of rheumatic syndromes induced by ICPI is variable. In general, inflammatory
arthritis usually appears around 8 weeks after initiation of therapy, but some patients may develop
arthritis even several months after treatment withdrawal [37,39,43,44].
The symptoms of patients who develop psoriatic arthritis-like syndromes are heterogeneous,
including nail involvement, distal interphalangeal arthritis, enthesitis and less frequently,
axial inflammatory pain (Figure 3). Patients with PMR due to ICPI may present with a mild increase of
acute phase reactants, and response to corticosteroids might be unsatisfactory compared to the classic
syndrome [37].
Although much more uncommon than articular manifestations, case series of sicca syndrome and
sarcoid-like reactions have been reported. Moreover, cases of well-defined systemic vasculitis, such as
giant cell arteritis or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and sporadic
cases of systemic erythematous lupus, anti-phospholipid syndrome and scleroderma reactions have
also been identified during ICPI treatment [37,45].
Since immune phenomena are predominantly T-cell mediated, autoantibodies are not usually
seen in patients with rheumatic syndromes related to ICPI. However, it is important to bear in mind
that some autoantibodies (anti-nuclear antibodies, anti-neutrophil cytoplasmic antibodies, rheumatoid
factor or antiphospholipid antibodies) are not uncommon at low titres in the elderly population with
active neoplasms [37,39].
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Figure 3. Symmetric distal swelling of interphalangeal joints with painful erythema in periarticular structures.
Given the increase in the use of ICPI for different solid and haematological neoplasms, it is not
uncommon for some patients with underlying rheumatic diseases to receive ICPI. Clinical flares are not
infrequent in these patients, but the use of ICPI is not contraindicated. An interesting fact is that cancer
patients presenting rheumatic manifestations or other irAEs are likely to respond to ICPI treatment
(85%) and may have a better oncologic prognosis than those patients without irAEs [46,47].
The treatment of these rheumatic syndromes must be based on shared decision making between
the rheumatologist or another specialist in autoimmune diseases and the referring specialist prescribing
ICPI treatment. Recently, the American Society of Clinical Oncology (ASCO) proposed a guideline for
the diagnosis, classification and treatment of irAEs of ICPI including rheumatic syndromes [40]. Low to
moderate doses (0.5 mg/kg/day) of oral corticosteroids are the standard treatment for inflammatory
rheumatic side effects related to ICPI.
Non-steroidal anti-inflammatory drugs (NSAIDs), analgesics and/or physiotherapy are
recommended for non-inflammatory conditions. There is usually no need to stop or even modify
ICPI treatment. In some cases, with severe polyarthritis, intravenous methylprednisolone pulses may
be needed for a short period of time (125 mg/day). In a small proportion of patients with persistent
synovitis, steroid-sparing treatments are recommended to minimise side effects. The therapy of choice
in these cases is disease modifying anti-rheumatic drugs (DMARDs) used in inflammatory arthropathies
usually involving oral or subcutaneous methotrexate at standard doses (10–20 mg per week). In some
severe cases, discontinuation of ICPI therapy is necessary. In addition, there are some anecdotal reports
of biologic DMARD use in patients with ICPI-induced inflammatory arthropathies, mainly anti-tumour
necrosis factor (TNF) therapies. Systemic vasculitis (giant cell arteritis or ANCA-associated vasculitis)
should be treated as classic entities (corticosteroids ± immunosuppressant drugs), and ICPI must
usually be stopped. Management of sicca syndrome and sarcoid-like reactions is conservative with
symptomatic treatment, and ICPI can usually be continued.
2.5. Endocrine
Endocrine toxicity is one of the most frequent toxicities associated with both anti-CTLA-4 and
anti-PD1/anti-PDL-1. Although the different types of ICPI have been associated with both thyroid
disorders and hypophysitis, the first is generally correlated with anti-PD1/anti-PDL-1 and the second
to anti-CTLA-4. The onset is around 7–8 weeks, although it can appear after the first dose and years
after ICPI discontinuation. Combined therapy with anti-PD1/anti-PDL-1 and anti-CTLA-4 is associated
with a higher incidence of endocrine toxicity, early onset (during the first month) and polyglandular
and severe presentations (G3-G4) [48].
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Little evidence is available on susceptibility markers for endocrine irAEs associated with ICPI.
Therefore, the best approach is: (1) to closely monitor ICPI-treated patients for clinical and analytical
signs of endocrine dysfunction before and during ICPI treatment (Figure S2), and (2) to treat irEAs
early [49]. Notably, the use of corticosteroids at high doses does not modify the grade of glandular
involvement, the recovery of which depends on the type of affected gland, and no prognostic markers
have been identified yet. Moreover, endocrine toxicity seems to be correlated with the efficacy of ICPI
and a higher survival rate, but the evidence on this issue is still limited [50,51].
Thyroid disorders are the most frequent endocrine irAEs, especially in association with
anti-PD-1/anti-PDL-1 (4–40%) [52,53]. In general, the clinical presentation consists of silent thyroiditis
diagnosed in blood tests with elevated free-T4 and suppressed thyroid stimulating hormone (TSH).
Thyroiditis may progress to transient thyrotoxicosis, euthyroidism or hypothyroidism (up to 30%).
Sporadic cases of Graves’ disease and thyroid ophthalmopathy have been described in association with
anti-CTLA-4 treatment. Presentation is usually G1–G2 and thyroid storm or myxoedema are extremely
rare. Previous thyroid disease or an endocrinological thyroid-related irAE are not contraindications for
ICPIs. In thyrotoxicosis or severe hypothyroidism, ICPI should be withheld. Aetiological diagnosis
may require anti-antiperoxidase (thyroid peroxidase (TPO)) antibodies for hypothyroidism and
anti-TSH receptor antibodies, thyroid scintigraphy and/or doppler ultrasound in hyperthyroidism.
When the patient presents with TSH > 10 mIU/L or between 5–10 mIU/L with positive anti-TPO or
clinical symptoms of hypothyroidism, replacement treatment is required (starting with 0.8 mcg/kg/d,
25–50 mcg/d in older people or those with comorbidities, mainly cardiac, and scaling up to 1.6 mcg/kg/d
approximately). In asymptomatic thyrotoxicosis, silent monitoring can be proposed; in symptomatic
thyrotoxicosis beta-blockers are recommended and in Graves’ disease, anti-thyroid drugs should be
associated. Corticosteroid therapy should only be considered in clinically severe cases of thyrotoxicosis.
Recovery of thyroid function is potential but unpredictable (up to 75% in hyperthyroidism and up to
15% in hypothyroidism) [48,49].
Hypophysitis is more frequent in patients receiving anti-CTLA-4 (up to 0–17%), especially in
males around 60 years-old and 2–3 months after beginning ICPI [52,53]. The clinical presentation
may be related to an increase in gland volume and compression symptoms (headache and/or visual
disturbances) or may be related to hormonal dysfunction (asthenia, decreased libido and amenorrhoea).
The gonadal and thyroid axes are almost always affected (85–100%) but with a high probability of
recovery. On the contrary, the corticotropic axis is less affected (50–73%), but the probability of recovery
is very low (0–15%). Diabetes insipidus is rare. When hypophysitis is suspected, blood electrolytes
and hormone tests are recommended before treatment (Figure S3). Pituitary magnetic resonance
imaging (MRI) should also be performed to rule out pituitary metastasis or haemorrhages, taking into
account that a normal image does not rule out the diagnosis of hypophysitis [49]. On the other hand,
anti-PD-1/anti-PDL-1 drugs have been associated with an isolated reduction in adrenocorticotropic
hormone (ACTH) levels, which appears around the 7th month of treatment with high variability.
Symptoms of hypocortisolism are more frequent with anti-PD-1/anti-PDL-1 than with anti-CTLA-4:
headache is rare, and hyponatremia is more prevalent. MRI is generally normal [54]. The management
of hypophysitis is summarised in Figure S3 [49].
Other less frequent endocrine irAEs (insulitis, pancreatitis, and adrenalitis) are described in
Text S1.
2.6. Liver
Hepatotoxicity due to the use of ICPI has been described in 3 to 9% of patients treated with
anti-CTLA4, being of 1 to 4% in patients receiving anti-PD1, and 18% in those treated with a combination
of both drugs [55,56]. Severe hepatitis (grade 3 or 4) occurs in approximately 3.5% of patients [24].
Liver toxicity generally manifests within the first 2 months of therapy, but it can also appear up to
6 months after starting ICPI treatment [57]. Most patients are asymptomatic, being diagnosed within
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the context of liver test abnormalities. However, it is important to bear in mind that immunotherapy is
the cause of the increase in liver enzymes in only 16.7% of patients undergoing ICPI treatment [58].
During evaluation of patients with increased liver enzymes during ICPI treatments, it is important:
(1) to determine the severity of liver dysfunction using the CTCAE scale in addition to parameters of
liver synthesis (international normalised ratio (INR) and albumin), and (2) to rule out other causes
of increased liver enzymes, including alcohol consumption, concomitant medications (drug-induced
liver damage), use of herbal products or over-the-counter medications, viral hepatitis (A, B, C, E),
idiopathic autoimmune hepatitis, hepatic or portal vein thrombosis, non-alcoholic fatty liver disease
or progression of cancer [40,59]. A liver biopsy should be considered in patients with grade 3 or 4
hepatitis to evaluate the degree of liver inflammation, and to rule out other causes of liver disease [57].
However, the performance of liver biopsy should not delay treatment in patients with liver dysfunction
(bilirubin >2.5 mg/dL and INR >1.5).
Less frequently, the bile duct can be the target of the ICPI-induced liver damage. The clinical
manifestations are similar to those of patients with obstructive cholangitis (fever, abdominal pain
and jaundice). Liver tests are characterised by an increase in alkaline phosphatase and γ-glutamyl
transferase. MRI cholangiography shows bile duct dilation and hypertrophy [60].
Treatment of liver toxicity is based on the severity (Table 1). In patients with grades 1 and 2
hepatitis, monitoring is essential and withholding ICPI therapy is necessary in those with grade 2
hepatitis. In patients with more severe liver involvement (grades 3 or 4), ICPI treatment discontinuation
is mandatory, and corticosteroid therapy (0.5–1 mg/kg/d) should be administered to patients with
grade 4 liver toxicity, and those with grade 3 and signs of liver dysfunction, severe inflammation in the
liver biopsy or worsening of liver tests [24,59,61,62].
2.7. Nervous System
Neurologic AEs in patients treated with IPCI are uncommon but are becoming increasingly
recognised. They are usually mild (grade 1–2), manifesting with non-specific and transient symptoms
(headache, dizziness, paresthesia), but in some cases neurologic complications may be severe
(grade 3–4) and the spectrum of symptoms highly heterogeneous (aseptic meningitis, encephalitis,
posterior reversible encephalopathy syndrome, cerebellitis, myelitis, mononeuritis, polyneuropathy
and myasthenia). Overall, the reported frequency is 4% for anti-CTLA4, 6% for anti-PD1 and 12%
when the two treatments are combined. However, the frequency of moderate-severe events is less than
1% for all types of ICPI [63,64]. Neurologic irAEs usually appear during the first 4 months, with a
median of 6 weeks after treatment initiation, but may develop later. The clinical course may evolve
rapidly and lead to severe disability or death. Early identification is crucial since the symptoms may
be reversible with adequate diagnosis and treatment [65]. Myasthenia and encephalitis are associated
with anti-PD1 whereas other neurologic AEs such as meningitis or Guillain–Barré-like syndrome
are associated with anti-CTLA-4. Myasthenia has an early onset, and concurrent myocarditis and
myositis are frequent, with a high fatality [66]. In patients with cancer the use of ICPI can potentiate
paraneoplastic mechanisms (an immune response that reacts with common antigens expressed by
tumoural and neural cells). Recognition of classical paraneoplastic neurological syndromes (limbic
encephalitis, encephalomyelitis, cerebellar degeneration, sensory neuronopathy, enteric neuropathy or
Lambert–Eaton myasthenic syndrome) or the detection of onconeural or neuronal-surface antibodies
may have implications in patient treatment and outcomes [67]. Treatment with anti-PD1 or anti-PD-L1
has been shown to worsen or trigger paraneoplastic syndromes associated with a very severe form of
encephalitis [68].
After ruling out cancer progression and infectious or metabolic causes of symptoms in patients
with suspected neurologic irAE, the consultant neurologist can help to characterise the neurologic
involvement and guide the additional work-up and management. The diagnostic algorithm depends
on the profile of symptoms and may include brain and spine MRI (to differentiate from stroke,
leptomeningeal spread or metastatic disease), analysis of cerebrospinal fluid (typically shows elevated
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protein levels with lymphocytic pleocytosis), electroencephalogram, electromyogram and antibody
studies. In severe cases, ICPI should be discontinued [69]. Treatment strategies are shown in
Table 1, and in most cases include corticosteroids, intravenous immunoglobulins or plasma exchange,
and cyclophosphamide or rituximab (in refractory cases or patients with proven paraneoplastic
disease). Infliximab, tocilizumab, mycophenolate, cyclosporine and natalizumab have been used in
anecdotal reports.
2.8. Eye
The eye is an immune-privileged site and it is known that excessive immune response is
suppressed by local and systemic mechanisms [70]. The ocular side effects related to ICPI are generally
immune-related. Their incidence is approximately 1% [71–73] and they usually appear between 6 to
12 weeks after starting ICPI therapy [72]. Ocular side effects have most frequently been reported with
anti-CTLA4, and comparatively more frequent with anti-PD1 than with anti-PDL-1 [71]. The association
of multiple ICPI increases the risk of adverse ocular effects [71,74,75]. They may affect different parts of
the visual system (orbit and ocular adnexa, ocular surface, retina, uveal tract, extraocular muscles and
optic nerve) and are usually associated with other systemic adverse effects [71,72]. Prompt detection is
mandatory since this can prevent structural damage with irreversible vision loss.
Ophthalmic side effects most frequently present as dry eye (1–24%) [71,76,77] and uveitis
(1%) [71]. Dry eye can be managed with artificial tears or topical cyclosporine in severe
cases [73,74]. Uveitis usually affects the anterior segment (anterior uveitis), but it can also affect
the posterior segment (posterior uveitis), mimicking autoimmune uveitis (including Birdshot disease,
Voght–Koyanagi–Harada syndrome) or severe retinal vasculitis [73,78–80]. In most cases, posterior
uveitis needs systemic or intravitreal corticosteroids, intravenous immunoglobulin (IVIG) and more
potent immunosuppression is needed in severe cases. The side effect most frequently observed
involving the orbit and adnexa is myasthenia gravis (MG), which can produce diplopia and/or ptosis
and can be associated with systemic symptoms such as respiratory distress. This complication can
be effectively managed with systemic corticosteroids and in some cases, plasma exchange or IVIG is
needed [81,82].
Ocular side effects rarely oblige ICPI treatment discontinuation or delay, although this may need
to be considered in cases with severe visual loss or the risk of loss. However, ocular side effects are
often associated with systemic side effects that can dictate the course of the treatment (Table S2).
2.9. Heart
Cardiotoxic effects of ICPI are infrequent but may be potentially serious. According to recent
registers and meta-analyses, the incidence is 1–2% [83]. The onset is usually early after exposure
to ICPI, with a median of 65 days (equivalent to 3 cycles), although it may appear after the first
dose [84]. The manifestations are varied [85] and include: myocarditis, conduction abnormalities,
coronary disease, non-inflammatory left ventricular dysfunction or pericarditis with or without
pericardial effusion. Myocarditis is usually of autoimmune type mediated by T lymphocytes and
is characterised by elevated troponin levels and systolic ventricular dysfunction in up to half of the
cases [86]. Elevation of troponin values and the appearance of symptoms are fundamental to decide
whether immunotherapy should be temporarily or permanently suspended and immunosuppressive
treatment initiated. Arrhythmic disorders caused by diffuse or direct myocardial inflammation of the
His-Purkinje system include first, second or third degree atrioventricular blocks and supraventricular
or ventricular arrhythmias. Coronary disease can be manifested by the rupture of atherosclerotic
plaque or due to coronary vasculitis or vasospasm. Systolic ventricular dysfunction can be presented in
the form of dilated cardiomyopathy or Tako–Tsubo syndrome and occurs with elevation of natriuretic
peptides as well as contractility abnormalities in cardiac imaging tests. In case of cardiac tamponade,
urgent pericardiocentesis is needed. The global management of immune-mediated cardiotoxicity
should be assessed jointly among the specialists involved and includes: (1) consider interrupting
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therapy (usually transiently), (2) initiating cardiological therapies (drugs, cardioversion, pacemaker
implantation, pericardiocentesis, ventricular assist devices) and (3) initiation of immunosuppression
(methylprednisolone as first option). Table S3 shows the main cardiac irAEs and recommendations.
2.10. Muscle
Previous data suggest that PD1/PDL1 inhibitor-associated myopathy may present with a
wide range of clinical manifestations and degrees of severity including MG [81,87,88], necrotising
myopathy [89–91] or even lethal cardiomyopathy [92–95]. The identification of new neuromuscular
symptoms in patients receiving anti-PD1 antibodies may be a challenge, as these patients may be at
greater risk of developing muscular complications either related to their underlying disease or as
a result of an irAE. With regard to histological features, myopathy due to ICPI is characterised by
necrosis with a large component of macrophage cells in clusters mimicking a pseudo-granulomatous
pattern [89]. Myopathy due to ICPI appears in the muscle biopsy as a unique and characteristic
pattern of inflammatory changes, far from any known inflammatory myopathy. When suspected,
ICPI treatment discontinuation is recommended. High dose corticosteroid treatment is the first line
treatment. The addition of IVIG or plasma exchange might be required in severe forms [63,96,97].
2.11. Kidney
ICPI can produce acute renal dysfunction (ARD) due to both its negative effect on the mechanisms
of immunological tolerance, as well as the release of various cytokines (interleukin 6, TNF alpha,
interferon gamma, CXCL10) and antibodies with direct toxic effect on renal tubular cells [98].
Initially, renal function deterioration was described in less than 1% of patients treated with
ipilimumab, nivolumab and pembrolizumab. However, subsequent studies have confirmed a
progressive increase in the frequency of grades 3–4 ARD [99,100]. In a study of 3695 patients
under treatment with ICPI, Cortazar et al. [101] reported that the frequency of ARD was 2.2%, and 0.6%
required dialysis. Subsequently, single centre studies [98] reported that the presence of ARD varied
between 10–29% if all cases with significant elevation in creatinine levels were included. In addition to
the alteration in renal function, the presence of haematuria (16%), eosinophilia (21%), hypertension
(11%), pyuria (68%) and in a few cases, nephrotic syndrome, were also recorded. In 12 out of 13 patients
in whom kidney biopsy was performed, the lesion pattern was acute tubulointerstitial nephritis (ATIN),
the time of appearance of the lesion was 24–245 days after initiating treatment, 7 of 12 patients had
extrarenal manifestations before the diagnosis of ARD (1 concomitant) and 9 of 10 cases treated with
steroids presented complete or partial remission. These studies have also generated the hypothesis
about the possible role of ICPI as agents that increase the risk of the appearance of immunoallergic
ATIN associated with drugs widely used in clinical practice (non-steroidal anti-inflammatory drugs,
antibiotics or proton-pump inhibitors, among others).
In the context of renal transplantation, the use of ICPI may increase the risk of developing acute
rejection in up to 40–50% of patients [102].
2.12. Haematological
Haematological complications associated with ICPI treatment are rare. Autoimmune haemolytic
anaemia (AIHA) has been associated with the use of ICPI including PD-1, PD-L1 and CTLA-4 directed
antibodies. Although AIHA is an infrequent complication (<1%), it can be serious and immediate
treatment with steroids is required together with ICPI discontinuation. In the case of insufficient
response, the use of rituximab can be considered [103].
Other immune cytopenias, neutropenia, thrombocytopenia and even aplastic anaemia have
also been described with the use of ICPI. Careful multidisciplinary evaluation of the risk-benefits of
discontinuation of ICPI must be made according to the severity of the immune complication.
Hodgkin lymphoma patients undergoing allogeneic stem cell transplantation after salvage ICPI
therapy have been reported to present a higher number of severe complications, particularly early
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acute graft-versus host disease [104]. Individualised risk evaluation of each patient is required until
more data help to clarify such observations.
3. Critical Care of Severe irAEs
Although most irAEs related to ICPI are mild to moderate and are well managed in an outpatient
setting, up to 20% of cases can be severe and even life-threatening (CTCAE grades III and IV) and lead
to intensive care unit (ICU) admission [105].
The frequency of grades 3–4 irAE with anti-PD-1 and anti-PDL-1 seems to similar, being more
common with CTLA-4 inhibitors (30%) and with combinations of these inhibitors (up to 55%). Moreover,
the safety profile of ICPI varies among the different indications: melanoma has a higher risk of GI and
skin irAE and lower frequencies of pneumonitis [106]. A recent systematic review of ICPI irAE that
required ICU admission outside clinical trials showed that the most common events were perforated
colitis or enterocolitis (17.6%), fulminant myocarditis (15.3%), polyradiculoneuritis (12.9%), pericarditis
(10.6%) and MG (10.6%). Most of the reported cases concerned the anti-CTLA4 antibody ipilimumab in
monotherapy (40.0%). The median time from ICPI initiation to ICU admission was 1.4 (0.2–16) months
with a median number of two courses having been received [107].
The management of patients with severe irAE requires close collaboration among ICU specialists,
organ specialists and cancer specialists as well as the adoption of standardised treatment protocols to
ensure the best possible patient outcomes [105,106,108].
Discussions about the prognosis of the cancer patient and goals of care are mandatory. However,
in cases in which ICPI induces organ failure, ICU admission of these patients should be considered
due to their potential reversibility with treatment, at least for a time-limited trial [106], and this is even
more important taking into account that high-grade toxicity seems to be associated with high tumoural
response rates [109].
Treatment consists of supportive care and aetiological treatment. Regarding the first, mechanical
ventilation and vasopressors are most often used, although renal replacement therapies or even
extracorporeal life support may be needed [106,107]. Concerning aetiological therapy, for severe grades
3–4 irAE ICPI should be immediately discontinued and steroid treatment should be initiated as soon
as possible. Whenever possible, it is of utmost importance to rule out alternative diagnoses before
treatment, mainly infectious complications and cancer progression, although this may sometimes be
challenging, and combined treatment must, in the meantime, be started.
4. Nursing and Immunotherapy
The role of nurses in the management of patients with indication of immunotherapy is key to
patient education for the different treatments and for detecting AEs. The information transmitted
to patients should be structured through therapeutic education programmes. These programmes
facilitate knowledge in an organised manner, respecting individual needs and promoting the sensation
of order and safety [110,111]. The aim of patient education is: (1) to provide the necessary knowledge
to follow the treatments and maintain adherence, (2) to decrease anxiety and facilitate acceptance,
(3) to include patients as active members of the team [112] and (4) to anticipate most common side
effects and inform the patients of strategies to relieve symptoms.
It is necessary to have an easy access infrastructure that welcomes and provides confidence
to patients. It should be fast and dynamic to respond in case of AEs. Nursing consultation,
complemented with telephone contact, should be friendly and respond to clinical needs in order to
provide agile response.
Nurses’ training is essential in order to detect possible ICPI complications. Nurses should know
what to ask and how to respond, and should have experience and knowledge in the treatment as well
as the underlying disease to thereby be able to differentiate treatment complications.
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5. Conclusions
irAEs related to ICPI are relatively frequent and affect multiple organs and systems complicating
patient management. The involvement of different medical specialties and nurses (working jointly with
the oncologists), with in depth knowledge of the specific organ affected, increases our understanding
of the pathogenesis of irAEs and, more importantly, assures the best personalised care and treatment.
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